Neuroscience of Psychedelics with Dr David E. Nichols

Psychedelics can profoundly alter someone’s state of consciousness - bringing about significant shifts in perception of self and reality. 

So, as these substances increasingly make their way into mainstream therapy, understanding the biological blueprint of such unique and powerful experiences is a growing area of neuroscientific research today. 

On November 10th, we  hosted the legendary psychedelic neuroscientist David E Nichols. Having conducted pivotal psychedelic science research for over 40 years, publishing over 200 scientific reports on their molecular effects, David will be sharing his expertise to unravel the question:

“What happens to the brain on psychedelics?”

You will discover some of the fundamental scientific theories behind the effects and therapeutic mechanisms of psychedelics. 

Moreover, as a leading psychedelic chemist, David will also be talking about novel synthesised substances, and how they compare to classical psychedelics like LSD and psilocybin. Both molecularly and in the context of psychedelic therapy. 

So if you’re interested in science, consciousness, and mental health, be sure to watch this talk where we delve into the complex and fascinating world of psychedelic neuroscience.

SPEAKER

Dr David E. Nichols

David E. Nichols, PhD is currently an Adjunct Professor at the University of North Carolina, Chapel Hill, NC, is a Distinguished Professor Emeritus at the Purdue University College of Pharmacy and was the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology, where he taught and did research for 38 years. He is also Director of Molecular Pharmacology at Eleusis Therapeutics.

In 2004 he was named the Irvine H. Page Lecturer by the International Society for Serotonin Research, received the first Purdue Provost’s Outstanding Graduate Mentor award in 2006 and was named a Distinguished Alumnus by the University of Iowa College of Pharmacy in 2012. He began studying psychedelics as a graduate student in 1969.  

His lab synthesised DMT for Dr. Rick Strassman, the MDMA for MAPS Phase I and II clinical trials, and the psilocybin used for human clinical studies conducted at Johns Hopkins University. In 1993 he founded the Heffter Research Institute (HRI), which funded the first groundbreaking Phase I and II studies of psilocybin for the treatment of depression, and pilot studies for treating alcohol use disorder, and tobacco addiction. 

REFUNDS POLICY: Please note, we do not arrange refunds or exchanges. When possible we encourage reselling on Ticketswap.

ACCESS:  We do our best to include everyone in our events, regardless of health circumstances. If you have access requirements please email the event organiser directly to discuss. Many facilitators are able to offer reduced ticket prices for those truly unable to afford the ticket price. If this applies to you, do please get in touch with the event organiser.

For PSYCHEDELIC KNOWLEDGE AND RESOURCES please check out the Psychedelic Society website. 

Our facilitators have agreed to our code of conduct. Learn about our procedure for raising concerns

MEMBERS of the Psychedelic Society get a discount off almost all of our events.
Join from £5 a month and become part of this amazing community with invites to special events and more.